Is it time for Peru to adopt the nine-valent vaccine?

Rodríguez G.V.; Kajatt O.G.; Orbegozo A.M. · Revista Peruana de Ginecologia y Obstetricia (2024) · DOI: 10.31403/rpgo.v70i2708

Resumen

Cervical cancer remains a challenge worldwide, especially in middle- and low-resource countries. HPV vaccination is one of the most important weapons included in the WHO's goals for 2030. The need to use a single dose is increasingly accepted in various national programs. The comparison of one, two, and three doses of HPV vaccines is very important to understand the changes occurring in the national policies of different countries. In Peru, the national vaccination program uses a single dose of the tetravalent vaccine from 9-18 years of age, gender-neutral.

Instituciones: Universidad de Piura